Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy & Haemorrhage

Status Completed

Clinical Trial Summary

The purpose of this research is to determine whether giving severely injured adults a drug called tranexamic acid (TXA) as soon as possible after injury will improve their chances of survival and their level of recovery at six months. After severe injury, a person may have uncontrolled bleeding that places them at high risk of bleeding to death. Coagulation (the formation of blood clots) is an important process in the body that helps to control blood loss. Up to a quarter of people that are severely injured have a condition called acute traumatic coagulopathy. This condition affects coagulation and results in the break down of blood clots (fibrinolysis) that can lead to increased blood loss and an increased risk of dying. TXA is an anti-fibrinolytic drug that might help to reduce the effects of acute traumatic coagulopathy by preventing blood clots from breaking down and helping to control bleeding. In Australia, TXA is approved for use by the Therapeutic Goods Administration (TGA) to reduce blood loss or the need for blood transfusion in patients undergoing surgery (i.e. cardiac surgery, knee or hip arthroplasty). Recent evidence from a large clinical trial (CRASH-2) showed early treatment with TXA reduced the risk of death in severely injured patients, however the majority of patients involved in the study were injured in countries where prehospital care is limited and rapid access to lifesaving treatments is limited compared to that available in countries like Australia and New Zealand. It is unclear whether TXA will reduce the risk of death to the same degree when it is given alongside other lifesaving treatments that are available to patients soon after injury in these countries. The hypothesis is that TXA given early to injured patients who are at risk of acute traumatic coagulopathy and who are treated in countries with systems providing advanced trauma care reduces mortality and improves recovery at 6-months after injury.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02187120
Study type	Interventional
Source	Monash University
Contact
Status	Completed
Phase	Phase 3
Start date	July 28, 2014
Completion date	September 7, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04554212` - Blood Flow Restriction Training After Patellar INStability	N/A
Suspended	`NCT02932176` - Machine Learning for Handheld Vascular Studies
Recruiting	`NCT04803253` - Study of the Social and Professional Reintegration Improvements Using a Set of Solutions for Upper Limb Amputation	N/A
Completed	`NCT00116337` - Spinal Cord Stimulation to Restore Cough	N/A
Completed	`NCT03463720` - Outcome for Patients With War-Associated Extremity Wound Infection	N/A
Completed	`NCT03113253` - TRANexamic Acid to Reduce Bleeding in BURN Surgery	Phase 4
Not yet recruiting	`NCT05492903` - COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)	N/A
Terminated	`NCT02909231` - One-year Patient Reported Outcomes Following Hospitalization for Trauma	N/A
Completed	`NCT02432456` - Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients	Phase 4
Completed	`NCT02744144` - Wound Bacterial Microbiota and Their Antibiotic Resistance	N/A
Completed	`NCT02266771` - Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice	N/A
Completed	`NCT02394821` - Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide	Phase 3
Not yet recruiting	`NCT01665963` - Efficacy of TopClosure(C)System in Healing Complicated Pacemaker Wounds	N/A
Completed	`NCT00151112` - Comparison of Two Different Procedures for Plexus Anesthesia	N/A
Not yet recruiting	`NCT03872544` - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting	`NCT04596124` - Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze	N/A
Recruiting	`NCT05800834` - Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds	Phase 2
Enrolling by invitation	`NCT03880188` - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Terminated	`NCT04775316` - Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing
Enrolling by invitation	`NCT03312504` - Implementing a School Prevention Program to Reduce Injuries Through Neuromuscular Training	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study) — PATCH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms